title: NCCN Awarded $2 Million in Research Funding  from Infinity Pharmaceuticals to Study Duvelisib in  Hematologic Malignancies.
mesh_terms: D004345:Drug Industry / Q000191:economics; D015507:Drugs, Investigational / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D007546:Isoquinolines / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D011687:Purines / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D012109:Research Support as Topic
chemical_list: D015507:Drugs, Investigational; D007546:Isoquinolines; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors; D011687:Purines; C586691:duvelisib